BR112022024533A2 - Formulação compreendendo daprodustat - Google Patents
Formulação compreendendo daprodustatInfo
- Publication number
- BR112022024533A2 BR112022024533A2 BR112022024533A BR112022024533A BR112022024533A2 BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2 BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2
- Authority
- BR
- Brazil
- Prior art keywords
- daprodustat
- formulation including
- immediate release
- release tablet
- aspects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041403P | 2020-06-19 | 2020-06-19 | |
| US202063043292P | 2020-06-24 | 2020-06-24 | |
| PCT/EP2021/066386 WO2021255159A1 (en) | 2020-06-19 | 2021-06-17 | Formulation comprising daprodustat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024533A2 true BR112022024533A2 (pt) | 2022-12-27 |
Family
ID=76730508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024533A BR112022024533A2 (pt) | 2020-06-19 | 2021-06-17 | Formulação compreendendo daprodustat |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230225977A1 (https=) |
| EP (1) | EP4167967A1 (https=) |
| JP (1) | JP7797425B2 (https=) |
| CN (1) | CN115697307A (https=) |
| BR (1) | BR112022024533A2 (https=) |
| CA (1) | CA3180509A1 (https=) |
| WO (1) | WO2021255159A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024521491A (ja) * | 2021-06-18 | 2024-05-31 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | ダプロデュスタットおよびその前駆体の新規な製造方法 |
| WO2024257063A1 (en) * | 2023-06-16 | 2024-12-19 | Glenmark Life Sciences Limited | Solid dispersion of daprodustat and a process for the preparation thereof |
| WO2025087207A1 (zh) * | 2023-10-24 | 2025-05-01 | 杭州安道药业有限公司 | 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| CN101773498B (zh) * | 2009-12-30 | 2012-06-20 | 青岛黄海制药有限责任公司 | 一种含有非布司他的口服缓控释制剂的制备方法 |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| SI3881833T1 (sl) * | 2015-06-30 | 2024-03-29 | Genentech, Inc., | Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet |
| CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| PH12018000227A1 (en) * | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| JP2020533396A (ja) | 2017-09-15 | 2020-11-19 | クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド | Ｇｓｋ１２７８８６３の結晶形及びその製造方法並びに医薬用途 |
| TWI843707B (zh) * | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| CN112955130A (zh) * | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| EP3880663A1 (en) * | 2018-11-15 | 2021-09-22 | Teva Pharmaceuticals International GmbH | Solid state forms of daprodustat and process for preparation thereof |
-
2021
- 2021-06-17 WO PCT/EP2021/066386 patent/WO2021255159A1/en not_active Ceased
- 2021-06-17 CA CA3180509A patent/CA3180509A1/en active Pending
- 2021-06-17 CN CN202180043608.0A patent/CN115697307A/zh active Pending
- 2021-06-17 EP EP21736531.1A patent/EP4167967A1/en active Pending
- 2021-06-17 JP JP2022577794A patent/JP7797425B2/ja active Active
- 2021-06-17 US US18/010,245 patent/US20230225977A1/en active Pending
- 2021-06-17 BR BR112022024533A patent/BR112022024533A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023532223A (ja) | 2023-07-27 |
| CA3180509A1 (en) | 2021-12-23 |
| US20230225977A1 (en) | 2023-07-20 |
| JP7797425B2 (ja) | 2026-01-13 |
| WO2021255159A1 (en) | 2021-12-23 |
| EP4167967A1 (en) | 2023-04-26 |
| CN115697307A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022024533A2 (pt) | Formulação compreendendo daprodustat | |
| MX2017014082A (es) | Nuevas proteinas especificas para cd137. | |
| BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| BR112016007479A2 (pt) | regimes de dosagem de imunoconjugado de anti-folr1 | |
| BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
| BR112016028672A2 (pt) | análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo | |
| CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
| ECSP12012024A (es) | Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| AR063760A1 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
| MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112023024209A2 (pt) | Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44 | |
| MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
| BR112023019668A2 (pt) | Composição farmacêutica para prevenir ou tratar fibrose | |
| BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
| BR112014021602A2 (pt) | uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide | |
| BR112018074152A2 (pt) | métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico | |
| BR112014027047A2 (pt) | nova formulação | |
| AR094289A1 (es) | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |